Methods for treating chronic obstructive pulmonary disease (COPD)

• US 20030232048A1
• Filed: 03/18/2003
• Published: 12/18/2003
• Est. Priority Date: 03/19/2002
• Status: Abandoned Application

• Current Assignee: Amgen Fremont Inc. (Amgen Inc.)
• Original Assignee: Amgen Fremont Inc. (Amgen Inc.)
• Inventors: Kudlacz, Elizabeth M., Showell, Henry J., Gladue, Ronald P., Yang, Xiao-dong, Bell, Gregory
• Application Number:
  US10/392,635
• Publication Number:
  US 20030232048A1
• Time in Patent Office: Days
• US Class Current: 424/141.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 2317/21 from primates, e.g. man

Abstract

The present disclosure relates to methods of treating Chronic Obstructive Pulmonary Disease (COPD) and its various indications, particularly including chronic bronchitis, emphysema, and irreversible asthma. Treatment regimens generally include the administration of anti-interleukin-8 antibodies to the patient to reduce the severity of an inflammatory response by the patient'"'"'s immune system.

Claims

1. A method of treating a patient suffering from symptoms of Chronic Obstructive Pulmonary Disease (COPD) comprising administering an amount of an antibody specific for human interleukin-8 effective to reduce said symptoms.

2. The method of claim 1, wherein the antibody neutralizes said human interleukin-8 in the patient.

3. The method of claim 1, wherein the antibody down-regulates the activity of interleukin-8 in the patient.

4. The method of claim 1, wherein the antibody is administered by one or more of the routes selected from the group consisting of intravenous, intraperitoneal, inhalation, intramuscular, subcutaneous and oral.

5. The method of claim 1, wherein the antibody is a monoclonal antibody.

6. The method of claim 1, wherein the antibody is a fully human antibody.

7. The method of claim 6, wherein the fully human antibody is an ABX-IL8 antibody.

8. A method of treating a patient suffering from symptoms of chronic bronchitis comprising administering an amount of an antibody specific for interleukin-8 effective to reduce said symptoms.

9. The method of claim 8, wherein the antibody neutralizes said human interleukin-8 in the patient.

10. The method of claim 8, wherein the antibody down-regulates the activity of interleukin-8 in the patient.

11. The method of claim 8, wherein the antibody is administered by one or more of the routes selected from the group consisting of intravenous, intraperitoneal, inhalation, intramuscular, subcutaneous and oral.

12. The method of claim 8, wherein the antibody is a monoclonal antibody.

13. The method of claim 8, wherein said antibody is a fully human antibody.

14. The method of claim 13, wherein the fully human antibody is an ABX-IL8 antibody.

15. A method of treating Chronic Obstructive Pulmonary Disease (COPD) in a human subject, comprising the step of administering to said subject a therapeutically effective amount of an antibody specific for interleukin-8, formulated in a pharmaceutically acceptable vehicle.

16. The method of claim 15, wherein the antibody neutralizes said human interleukin-8 in the patient.

17. The method of claim 15, wherein the antibody down-regulates the activity of interleukin-8 in the patient.

18. The method of claim 15, wherein the antibody is administered by one or more of the routes selected from the group consisting of intravenous, intraperitoneal, inhalation, intramuscular, subcutaneous and oral.

19. The method of claim 15, wherein the antibody is a monoclonal antibody.

20. The method of claim 15, wherein said antibody is a fully human antibody.

21. The method of claim 20, wherein the fully human antibody is an ABX-IL8 antibody.

22. The method of claim 15 wherein the pharmaceutically acceptable vehicle comprises phosphate buffered saline.